Erica Schwartz testifies during her confirmation hearing to become director of the Centers for Disease Control and Prevention before the Senate Health, Education, Labor and Pensions Committee on July 15, 2026. (Photo by Finn Gomez/Getty Images) WASHINGTON — President Donald Trump’s pick to lead the Centers for Disease Control and Prevention didn’t appear to secure the support needed to take over the public health agency during a lengthy and often tense confirmation hearing Wednesday. While Dr. Erica Schwartz told lawmakers on the U.S. Senate Committee that oversees health policy she would “never betray the science,” she didn’t seem to win the trust of Democrats or key Republicans needed to advance. Chairman Bill Cassidy, R-La., repeatedly questioned Schwartz about whether she would follow the example set by former CDC Director Susan Monarez, who testified last year that she was fired after refusing to pre-approve vaccine recommendations or fire career officials for no reason. “...
A dispensary in St. Louis advertises to passersby. Nearly 34% of adolescents seeking treatment for cannabis use disorder in 2022 experienced an admission delay, according to a new study. (Photo by Rebecca Rivas/Missouri Independent) As federal officials consider whether to reclassify marijuana under federal drug law, a new study has found that more American teenagers seeking treatment for cannabis use disorder, known as CUD, are facing longer wait times before receiving care. The study, published in the American Journal of Preventive Medicine, analyzed national data from more than 124,000 adolescent admissions to publicly funded substance use treatment facilities between 2012 and 2022. Researchers found that after several years of decline, the share of young people experiencing delays in accessing treatment increased sharply. While overall adolescent cannabis use has leveled off or declined slightly over the past decade, some young people who use cannabis regularly develop CUD that ...